Agios Pharmaceuticals, Inc.
AGIO
$29.20
-$1.03-3.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 54.03M | 44.79M | 40.88M | 37.04M | 36.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 54.03M | 44.79M | 40.88M | 37.04M | 36.50M |
| Cost of Revenue | 345.88M | 340.02M | 324.78M | 310.03M | 305.45M |
| Gross Profit | -291.85M | -295.22M | -283.90M | -273.00M | -268.95M |
| SG&A Expenses | 180.28M | 180.37M | 177.63M | 167.30M | 156.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 526.16M | 520.38M | 502.41M | 477.33M | 462.24M |
| Operating Income | -472.13M | -475.59M | -461.53M | -440.29M | -425.74M |
| Income Before Tax | -413.80M | -410.14M | 694.33M | 710.23M | 717.97M |
| Income Tax Expenses | -1.02M | -8.88M | 44.24M | 44.24M | 44.24M |
| Earnings from Continuing Operations | -412.78 | -401.27 | 650.08 | 665.99 | 673.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -412.78M | -401.27M | 650.08M | 665.99M | 673.73M |
| EBIT | -472.13M | -475.59M | -461.53M | -440.29M | -425.74M |
| EBITDA | -466.96M | -470.31M | -456.28M | -434.71M | -420.08M |
| EPS Basic | -7.12 | -6.96 | 11.47 | 11.71 | 11.82 |
| Normalized Basic EPS | -4.46 | -4.45 | -4.30 | -4.15 | -4.08 |
| EPS Diluted | -7.12 | -6.96 | 11.04 | 11.28 | 11.39 |
| Normalized Diluted EPS | -4.46 | -4.45 | -4.28 | -4.12 | -4.06 |
| Average Basic Shares Outstanding | 231.88M | 230.63M | 229.43M | 228.30M | 227.23M |
| Average Diluted Shares Outstanding | 231.88M | 230.63M | 230.93M | 229.80M | 228.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |